How to buy Neurocrine Biosciences stock

Neurocrine Biosciences, Inc is a biotechnology business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 845 staff and has a trailing 12-month revenue of around USD$1 billion.

How to buy shares in Neurocrine Biosciences

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Neurocrine Biosciences. Find the stock by name or ticker symbol: NBIX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neurocrine Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neurocrine Biosciences, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Neurocrine Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Neurocrine Biosciences share price

Use our graph to track the performance of NBIX stocks over time.

Neurocrine Biosciences shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$72.14 - USD$136.2618
50-day moving average	USD$111.2582
200-day moving average	USD$103.494
Wall St. target price	USD$129
PE ratio	25.8606
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$4.16

Buy Neurocrine Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Neurocrine Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Neurocrine Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurocrine Biosciences financials

Revenue TTM	USD$1 billion
Operating margin TTM	31.31%
Gross profit TTM	USD$760.8 million
Return on assets TTM	13.46%
Return on equity TTM	46.2%
Profit margin	38.94%
Book value	$12.045
Market capitalisation	USD$10.1 billion

TTM: trailing 12 months

Shorting Neurocrine Biosciences shares

There are currently 4.1 million Neurocrine Biosciences shares held short by investors – that's known as Neurocrine Biosciences's "short interest". This figure is 6.3% down from 4.4 million last month.

There are a few different ways that this level of interest in shorting Neurocrine Biosciences shares can be evaluated.

Neurocrine Biosciences's "short interest ratio" (SIR)

Neurocrine Biosciences's "short interest ratio" (SIR) is the quantity of Neurocrine Biosciences shares currently shorted divided by the average quantity of Neurocrine Biosciences shares traded daily (recently around 910303.55555556). Neurocrine Biosciences's SIR currently stands at 4.5. In other words for every 100,000 Neurocrine Biosciences shares traded daily on the market, roughly 4500 shares are currently held short.

However Neurocrine Biosciences's short interest can also be evaluated against the total number of Neurocrine Biosciences shares, or, against the total number of tradable Neurocrine Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurocrine Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Neurocrine Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0442% of the tradable shares (for every 100,000 tradable Neurocrine Biosciences shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neurocrine Biosciences.

Find out more about how you can short Neurocrine Biosciences stock.

Neurocrine Biosciences share price volatility

Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $72.14 up to $136.2618. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.8394. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).

Neurocrine Biosciences overview

Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of Neurocrine Biosciences is owned by insiders or institutions?

  Currently 1.263% of Neurocrine Biosciences shares are held by insiders and 99.379% by institutions.

• How many people work for Neurocrine Biosciences?

  Latest data suggests 845 work at Neurocrine Biosciences.

• When does the fiscal year end for Neurocrine Biosciences?

  Neurocrine Biosciences's fiscal year ends in December.

• Where is Neurocrine Biosciences based?

  Neurocrine Biosciences's address is: 12780 El Camino Real, San Diego, CA, United States, 92130

• What is Neurocrine Biosciences's ISIN number?

  Neurocrine Biosciences's international securities identification number is: US64125C1099

• What is Neurocrine Biosciences's CUSIP number?

  Neurocrine Biosciences's Committee on Uniform Securities Identification Procedures number is: 64125C109